Stem Cell Therapeutics merger with Trillium completed
Stem Cell Therapeutics Corp., a Toronto-based life sciences company developing stem cell-related technologies, has completed its previously-announced merger with Trillium Therapeutics Inc. Shareholders of Toronto's Trillium, a specialist in immunotherapy and cancer stem cell research, voted for the deal, which provides them with cash and shares in the new company. Trillium has been backed by Canadian venture capital firms since 1997.
10 April 2013•3 mins read
